Liraglutide suppresses atrial electrophysiological changes
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
We have shown that a dipeptidyl peptidase 4 (DPP-4) inhibitor suppresses atrial remodeling in a canine atrial fibrillation (AF) model. Glucagon-like peptide-1 (GLP-1) is increased by DPP-4 inhibitors. However, it is not clear whether GLP-1 is involved in the suppression of atrial remodeling. In this study, we evaluated the effect of liraglutide (a GLP-1 analog) on atrial electrophysiological changes using the same canine AF model. We established a canine AF model using continuous 3-week rapid atrial stimulation in seven beagle dogs divided into two groups: a liraglutide group with four dogs (3-week atrial pacing with liraglutide (150 µg/kg/day) administration) and a pacing control group with three dogs (3-week pacing without any medicine). We evaluated the atrial effective refractory period (AERP), conduction velocity (CV), and AF inducibility every week during the protocol using implanted epicardial wires against the surfaces of both atria. In the pacing control group, the AERP was gradually shortened and the CV was decreased along the time course. In the liraglutide group, the AERP was similarly shortened as in the pacing control group (94 ± 4% versus 85 ± 2%, respectively; p = 0.5926), but the CV became significantly higher than that in the pacing control group after 2 and 3 weeks (95 ± 4 versus 83 ± 5%, respectively; p = 0.0339). The AF inducibility was gradually increased in the pacing control group, but it was suppressed in the liraglutide group (5 ± 9% versus 73 ± 5%; p = 0.0262). Liraglutide suppressed electrophysiological changes such as AF inducibility and CV decrease in our canine AF model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, in a canine AF model, liraglutide was found to suppress atrial electrophysiological changes such as AF inducibility and conduction velocity decrease [32].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [32]
Citations
Cites
Nattel, S., Maguy, A., Le Bouter, S., & Yeh, Y.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00014.2006 · Cited by 858
Atrial Remodeling and Atrial Fibrillation
Nattel, S., & Harada, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.555 · Cited by 736
Sodium Channel Mutations and Susceptibility to Heart Failure and Atrial Fibrillation
Olson, T. M. (2005) · JAMA · doi:10.1001/jama.293.4.447 · Cited by 554
Cardiac Fibrosis in Patients With Atrial Fibrillation
Dzeshka, M. S., Lip, G. Y. H., Snezhitskiy, V., & Shantsila, E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1313 · Cited by 552
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Molecular Mechanisms Underlying Ionic Remodeling in a Dog Model of Atrial Fibrillation
Yue, L., Melnyk, P., Gaspo, R., Wang, Z., & Nattel, S. (1999) · Circulation Research · doi:10.1161/01.res.84.7.776 · Cited by 357
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Sonne, D. P., Engstrøm, T., & Treiman, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 294
Tachycardia-Induced Changes in Na+Current in a Chronic Dog Model of Atrial Fibrillation
Gaspo, R., Bosch, R. F., Bou-Abboud, E., & Nattel, S. (1997) · Circulation Research · doi:10.1161/01.res.81.6.1045 · Cited by 256
Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149
Liu, Q., Anderson, C., Broyde, A., Polizzi, C., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 124
BOSCH, R. F., Scherer, C. R., Rüb, N., Wöhrl, S., Steinmeyer, K., Haase, H., Busch, A. E., Seipel, L., & Kühlkamp, V. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02922-4 · Cited by 114
Huang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Warbrick, I., & Rabkin, S. W. (2018) · Peptides · doi:10.1016/j.peptides.2018.05.009 · Cited by 26
Satoh, A., Niwano, S., Niwano, H., Kishihara, J., Aoyama, Y., Oikawa, J., Fukaya, H., Tamaki, H., & Ako, J. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0874-2 · Cited by 16
Self-citationIgarashi, T., Niwano, S., Niwano, H., Yoshizawa, T., Nakamura, H. K., Fukaya, H., Fujiishi, T., Ishizue, N., Satoh, A., Kishihara, J., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1170-0 · Cited by 15
Self-citationLebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 14
Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation.
Kishihara, J., Niwano, S., Niwano, H., Aoyama, Y., Satoh, A., Oikawa, J., Kiryu, M., Fukaya, H., Masaki, Y., Tamaki, H., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-3652.2014.02.03 · Cited by 13
Self-citation
Cited by
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
Bode, D., Pronto, J. R. D., Schiattarella, G. G., & Voigt, N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01038-6 · Cited by 111
“Consistent with these findings, liraglutide has also been shown to reduce AF susceptibility in a canine model of pacing-induced AF, an effect that was associated with an increase in atrial conduction velocity 244 .”
Bohne, L. J., Jansen, H. J., Dorey, T. W., Daniel, I. M., Jamieson, K. L., Belke, D. D., McRae, M. D., & Rose, R. A. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.01.005 · Cited by 79
Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease
Jansen, H. J., Bohne, L. J., Gillis, A. M., & Rose, R. A. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.05.002 · Cited by 74
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Indeed, in a canine AF model, liraglutide was found to suppress atrial electrophysiological changes such as AF inducibility and conduction velocity decrease [32].”
BackgroundPacker, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 70
Metadata
- Authors
- Nakamura, H., Niwano, S., Niwano, H., Fukaya, H., Murakami, M., Kishihara, J., Satoh, A., Yoshizawa, T., Ishizue, N., Igarashi, T., Fujiishi, T., & Ako, J.
- Affiliations
- Kitasato University (JP)
- Corresponding author
- Niwano, Shinichi
- ORCID
- Venue
- Heart and Vessels
- Published
- 2019-02-14
- Volume
- 34
- Issue
- 8
- Pages
- 1389-1393
- ISSN
- 0910-8327 (ISSN-L)
- 1615-2573
- OpenAlex
- W2914956213
- Cited by
- 35
- References
- 18
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 1 · 2020: 2 · 2019: 4
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Heart and Vessels (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- liraglutide, atrial fibrillation, atrial remodeling, atrial electrophysiology, atrial effective refractory period, atrial conduction velocity, atrial fibrillation inducibility, GLP-1 analogues, DPP-4 inhibitors, rapid atrial pacing
- MeSH terms
- Liraglutide, Animals, Atrial Fibrillation, Cardiac Pacing, Artificial, Dogs, Female, Heart Atria, Electrophysiological Phenomena, Atrial Remodeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.